Literature DB >> 29716887

Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade?

Antonino Carbone1, Annunziata Gloghini2, Carmelo Carlo-Stella3,4.   

Abstract

Epstein-Barr virus (EBV)-related and EBV-unrelated classical Hodgkin lymphomas (cHLs) are morphologically and phenotypically indistinguishable. However, the tumor microenvironment of EBV-related cHLs contains higher numbers of macrophages and higher expression levels of PD-L1 than that of EBV-unrelated cHLs. Moreover, viral oncoprotein LMP1 may sustain an immunosuppressive microenvironment by inducing/enhancing production of immunosuppressive cytokines and the expression of PD-1. The presence of enhanced immunosuppressive features in EBV-related cHL should make EBV-related cHL patients more susceptible to checkpoint blockade.
© 2018 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29716887     DOI： 10.1182/blood-2018-02-833806

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  Hodgkin Lymphoma: Biology and Differential Diagnostic Problem.

Authors:  Taishi Takahara; Akira Satou; Toyonori Tsuzuki; Shigeo Nakamura
Journal:  Diagnostics (Basel)       Date:  2022-06-20

2.  Indolent T cell lymphoproliferative disorder of the gastrointestinal tract: an uncommon case with lymph node involvement and the classic Hodgkin's lymphoma.

Authors:  Jie Wu; Long-Guang Li; Xiang-Yan Zhang; Li-Li Wang; Li Zhang; Yu-Jing Xiao; Xiao-Ming Xing; Dong-Liang Lin
Journal:  J Gastrointest Oncol       Date:  2020-08

Review 3.  Proteomic approaches to investigate gammaherpesvirus biology and associated tumorigenesis.

Authors:  Danielle L Chappell; Maria C White; Blossom Damania
Journal:  Adv Virus Res       Date:  2020-11-09       Impact factor: 9.937

Review 4.  Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?

Authors:  Selma Addou; Clémentine Sarkozy; Julien Lazarovici; Stéphane Champiat; Aspasia Stamatoullas; Fabrice Jardin; Vincent Ribrag; Aurélien Marabelle; Jean-Marie Michot
Journal:  Hum Vaccin Immunother       Date:  2021-06-08       Impact factor: 4.526

5.  Epstein Barr Virus-Associated Hodgkin Lymphoma.

Authors:  Antonino Carbone; Annunziata Gloghini
Journal:  Cancers (Basel)       Date:  2018-05-25       Impact factor: 6.639

6.  Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma.

Authors:  Kathryn Lurain; Ramya Ramaswami; Ralph Mangusan; Anaida Widell; Irene Ekwede; Jomy George; Richard Ambinder; Martin Cheever; James L Gulley; Priscila H Goncalves; Hao-Wei Wang; Thomas S Uldrick; Robert Yarchoan
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751

Review 7.  Virus-Driven Carcinogenesis.

Authors:  Yuichiro Hatano; Takayasu Ideta; Akihiro Hirata; Kayoko Hatano; Hiroyuki Tomita; Hideshi Okada; Masahito Shimizu; Takuji Tanaka; Akira Hara
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

Review 8.  Targeting immune checkpoints in hematological malignancies.

Authors:  Basit Salik; Mark J Smyth; Kyohei Nakamura
Journal:  J Hematol Oncol       Date:  2020-08-12       Impact factor: 17.388

9.  Genomic and immunologic correlates of LAG-3 expression in cancer.

Authors:  Anshuman Panda; Jeffrey A Rosenfeld; Eric A Singer; Gyan Bhanot; Shridar Ganesan
Journal:  Oncoimmunology       Date:  2020-05-22       Impact factor: 8.110

10.  EB virus-induced ATR activation accelerates nasopharyngeal carcinoma growth via M2-type macrophages polarization.

Authors:  Bo Zhang; Tianyu Miao; Xin Shen; Lirong Bao; Cheng Zhang; Caixia Yan; Wei Wei; Jiao Chen; Liying Xiao; Chongkui Sun; Jintao Du; Yan Li
Journal:  Cell Death Dis       Date:  2020-09-11       Impact factor: 8.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.